Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 8:2021:5534851.
doi: 10.1155/2021/5534851. eCollection 2021.

Update in the Management of ANCA-Associated Vasculitis: Recent Developments and Future Perspectives

Karla N Samman  1 , Carolyn Ross  1 , Christian Pagnoux  2 , Jean-Paul Makhzoum  1
Affiliations
Review

Update in the Management of ANCA-Associated Vasculitis: Recent Developments and Future Perspectives

Karla N Samman et al. Int J Rheumatol. .

Abstract

Significant progress has been made in the treatment of ANCA-associated vasculitides (AAV), notably in granulomatosis with polyangiitis and microscopic polyangiitis. Over the past few years, many innovative studies have changed the way we now induce and maintain remission in AAV; achieving remission while limiting treatment toxicity is the key. This article provides an in-depth, up-to-date summary of recent trials and suggests treatment algorithms for induction and maintenance of remission based on the latest guidelines. Future possible therapies in AAV will also be discussed.

PubMed Disclaimer

Conflict of interest statement

Dr. Pagnoux reports grants and personal fees from Roche, personal fees from ChemoCentryx, grants and personal fees from GSK, personal fees from Sanofi, personal fees from InflaRx GmbH, and personal fees from AstraZeneca, outside the submitted work; Dr. Makhzoum reports personal fees from Hoffmann-La Roche, outside the submitted work. The other authors have no conflicts of interest.

Figures

Figure 1
Figure 1
Timeline of hallmark trials of ANCA-associated vasculitis.
Figure 2
Figure 2
Suggested algorithm of induction therapy in severe GPA or MPA.
Figure 3
Figure 3
Suggested algorithm of maintenance therapy in severe GPA and MPA.
See this image and copyright information in PMC

References

    1. Jennette J. C., Falk R. J., Bacon P. A., et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis and Rheumatism. 2013;65(1):1–11. doi: 10.1002/art.37715. - DOI - PubMed
    1. Zarka F., Veillette C., Makhzoum J.-P. A review of primary vasculitis mimickers based on the Chapel Hill Consensus classification. International Journal of Rheumatology. 2020;2020 doi: 10.1155/2020/8392542.8392542 - DOI - PMC - PubMed
    1. Shi L. Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes. Rheumatology International. 2017;37(11):1779–1788. doi: 10.1007/s00296-017-3818-y. - DOI - PubMed
    1. Geetha D., Jefferson J. A. ANCA-associated vasculitis: core curriculum 2020. American Journal of Kidney Diseases. 2020;75(1):124–137. doi: 10.1053/j.ajkd.2019.04.031. - DOI - PubMed
    1. Mendel A., Ennis D., Go E., et al. CanVasc consensus recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis: 2020 update. The Journal of Rheumatology. 2021;48(4):555–566. doi: 10.3899/jrheum.200721. - DOI - PubMed

LinkOut - more resources